TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Compared to adults, children appear to require higher weight-based doses of rifapentine to
acheive comparable drug levels. TBTC Study 26, a study of the effectiveness and tolerability
of weekly rifapentine/isoniazid for three months versus daily isoniazid for nine months for
the treatment of latent tuberculosis infection, has been amended to include children ages
2-11 based on an initial single-dose study and pharmacokinetic modeling. Study 26PK evaluates
the adequacy of the doses chosen for young children enrolled in Study 26 with a single blood
draw, 24 hours after the third or subsequent weekly Study 26 dose of rifapentine and
isoniazid. An adult control is enrolled for each child enrolled.
Phase:
N/A
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development